BioStem Technologies (BSEM) Expected to Post Quarterly Earnings on Wednesday

BioStem Technologies (OTCMKTS:BSEM) is expected to be posting its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $6.3520 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

BioStem Technologies (OTCMKTS:BSEM) last released its earnings results on Thursday, May 14th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The company had revenue of $6.14 million for the quarter, compared to the consensus estimate of $5.70 million. On average, analysts expect BioStem Technologies to post $-2 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

BioStem Technologies Price Performance

OTCMKTS BSEM opened at $3.26 on Wednesday. The company has a 50-day simple moving average of $3.69 and a two-hundred day simple moving average of $4.65. BioStem Technologies has a 12-month low of $3.01 and a 12-month high of $11.54. The firm has a market cap of $58.09 million, a price-to-earnings ratio of -2.92 and a beta of 0.11.

Wall Street Analyst Weigh In

Separately, HC Wainwright started coverage on BioStem Technologies in a report on Wednesday, May 6th. They set a “buy” rating and a $9.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $9.00.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.